PD98059

目录号:S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059是一种非ATP竞争性的MEK抑制剂,无细胞试验中IC50为2 μM,特异性抑制MEK-1介导的MAPK激活;不直接抑制ERK1或ERK2。

规格 价格 库存 购买数量  
RMB 1099.68 现货
RMB 1213.08 现货
RMB 3845.73 现货
RMB 5489.52 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献49篇:

客户使用该产品的10个实验数据:

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017, 106:25-29. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述 PD98059是一种非ATP竞争性的MEK抑制剂,无细胞试验中IC50为2 μM,特异性抑制MEK-1介导的MAPK激活;不直接抑制ERK1或ERK2。
特性 PD98059不会抑制已经被c-Raf磷酸化的 MEK1
靶点
MEK1 [1]
(Cell-free assay)
2 μM
体外研究

PD98059 要么抑制本底的MEK1,要么抑制一种被部分激活的MEK突变体,该突变体是 218 和 222号位上丝氨酸突变为谷氨酸后形成的(MEK-2E), IC50 为2 μM. PD98059 不会抑制JNK和P38这两个 MAPK 的同系物. PD98059会高度选择性的抑制MEK, 因为对其它包括Raf 激酶, cAMP-依赖性激酶, 蛋白激酶C, v-Src, 表皮生长因子 (EGF) 受体激酶, 胰岛素受体激酶, PDGF 受体激酶, 和磷脂酰肌醇(-3)激酶等在内的一系列激酶都没有抑制性。 PD98059 会抑制经过PDGF刺激而活化的MAPK 和胸苷 进入 3T3 细胞, IC50分别为 ~10 μM 和 ~7 μM [1]。PD98059可以有效地阻止 MEK1 被Raf 或者MEK 激酶活化, IC50为4 μM, 可以微弱地 抑制MEK2被 Raf 活化, IC50 为50 μM。 在KB 和 PC12 细胞中, PD98059 不会抑制MKK4 和RK激酶这两个参与压力和白细胞介素-1介导的激酶级联反应的MEK的同系物的活化,在Swiss 3T3 细胞中也不会通过胰岛素或者表皮生长因子抑制p70 S6 激酶的活化[2]。PD98059会在不改变细胞生存能力的情况下完全阻断 神经生长因子(NGF)诱导的 PC12 细胞的分化[3] 。PD98059会以剂量依赖性的方式抑制培养在含有破骨细胞分化因子培养基中的 RAW264.7细胞的增值,进而导致TRAP阳性细胞数量明显下降[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NIT2bXJHfW6ldHnvckBCe3OjeR?= NYXWVFRXOjVizszN MlzlNUBp NXT6dmRV[my3boTzJJRp\SCEW3HdVE1qdmS3Y3XkJIlv[3KnYYPlJIlvKHCqb4PwbI8uS2itMTDhcoQheGixc4Doc{1GWktiZYjwdoV{e2mxbh?= NF\4S3EzPTd4OUG4NS=>
MCF-7  Mme5SpVv[3Srb36gRZN{[Xl? NGLXeY4yOCEQvF2= M3G3OlEhcA>? NIfPepBqdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>? NUToelZ5OjV5MkewNVE>
HepG2  NUL3SpFsTnWwY4Tpc44hSXO|YYm= M1;zRVExKM7:TR?= MVS1JIg> MVXicI9kc3NicHjvd5Bpd3K7bHH0[YQhVUGSS4OgbY5lfWOnZDDifUBmgG:pZX7veZMhXEeILd8yNS=> NFLTcoczPTV4MES4PC=>
HepG2  MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULqcJJZOjBizszN MkXwNlQhcA>? MWTzeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v MYWyOVU3ODR6OB?=
MDA-MB-231 NYfqcXF1TnWwY4Tpc44hSXO|YYm= M{i3ZlI2KM7:TR?= MnXBNk0{KGh? NYHHdFY4\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?= MkDENlU2PTV6N{W=
SW480 NVnXNlBqTnWwY4Tpc44hSXO|YYm= Ml\wNlDDqM7:TR?= NFTybGUyyqCq MX3y[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=> NEfT[G8zPTR2N{ixOi=>
HCT-15 NYXKbpNTTnWwY4Tpc44hSXO|YYm= M{[zflEhcA>? MYDheJRmdnWjdHXzJHBITTJvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrxsA> MoLqNlU1OzF2MkW=
HCT-15 M4XXemFxd3C2b4Ppd{BCe3OjeR?= MnnJNUBp MWDhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{ M{PxXFI2PDNzNEK1
786-O MmfpRZBweHSxc3nzJGF{e2G7 NHv0S|M2OMLizszN NF6xeHIzPCCq M3;PfJBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D NVnJbmhFOjR3MEi0O|Y>
A498 MoPURZBweHSxc3nzJGF{e2G7 M2n2Z|UxyqEQvF2= NVraXmxlOjRiaB?= MX\wc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?= NEOyOm8zPDVyOES3Oi=>
NHBE NHv3[oxHfW6ldHnvckBCe3OjeR?= M4TycFIwOjBizszN M4nhWVIhcA>? NGfFNHVifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC|ZXPy[ZRqd25? NXLYWXhPOjR2N{m1NlY>
A375 NHvBbYZE\WyuIFnueoF{cW:wIFHzd4F6 M4G5NFEx6oDVMkCgxtVO NY\DWIFDOjRiaB?= MonvdoVlfWOnczDt[Yxidm:vYTDj[YxtKGmwdnHzbY9v NHT1R|AzPDR4NkCzOi=>
HBMEC M{PNemZ2dmO2aX;uJGF{e2G7 MoT1NVAh|ryP NIr5dGIyKGh? NHTOSo5jdG:la4OgWmVITi2rbnT1Z4VlKEWyaFGyJIV5eHKnc4Ppc44> MUCyOFQ2QDl6Mh?=
HPAEpiCs  MmHuSpVv[3Srb36gRZN{[Xl? MV[zNEDPxE1? MUGxJIg> M3HOWolvcGmkaYTzJHRPTi4QsTDzeIlufWyjdHXkJJA1Oi:yNESgUWFRUyCyaH;zdIhwenmuYYTpc44> MW[yOFQ1OTh5MB?=
BeWo NHz4dWhHfW6ldHnvckBCe3OjeR?= NEm4WWsyOMLizszN NG\ZOm0zKGh? NX7acnNGcW6qaXLpeJMhTVKNMT:y NWrRcHhKOjR2M{O4OFY>
PC3  NULYc|JUSXCxcITvd4l{KEG|c3H5 M3mzbFUxKM7:TR?= MVKwMlUhcA>? MV;pcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m|wrC= NV3KeVdwOjR2MkS4PFk>
HGC-27 M37Y[GFxd3C2b4Ppd{BCe3OjeR?= NIDTOHQyKML3TR?= NXrmWnJQOSCq MmD5d5VxeHKnc4Pld{BTSURyMEGgdIx2eyCPSz2yNlA3NWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NXn3[GZoOjR2MU[zOFk>
MCF-7 NXK5Wo1TTnWwY4Tpc44hSXO|YYm= NXzPUoo6OTEEoN88US=> M4nQeFExNzNyIH3pci=> NV7yeHZtemWmdXPld{B1cGViVWTQMYRmeGWwZHXueEBGWkticHjvd5Bpd3K7bHH0bY9v NYWxVYs6OjR|OUC4NVk>
HUVECs MkPSSpVv[3Srb36gRZN{[Xl? Mm[yNVDDqM7:TR?= NVS3ZXhJOSCq NFLVXVBqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG|ZR?= MnT5NlQ{QDVzMEm=
HeLa MmLESpVv[3Srb36gRZN{[Xl? NYPYd5h1PTBizszN MofhNE42KGh? NFTtWpVjdG:la4OgWHJZNTFiboXjcIVieiCvaXfyZZRqd25iYX7kJHRZVkmSIHTve44uemWpdXzheIlwdg>? MYOyOFM4Pjh{Nx?=
HL-60  NUnuTldpTnWwY4Tpc44hSXO|YYm= MmjLNVAwOjBizszN M1XYU|EhcA>? MVLpcohq[mm2czD0bIXDqE5wIHPobY5mdnOrc3X4eJJi[3UEoHnu[JVk\WRiZHnm[oVz\W62aXH0bY9vKGmwdH:g[5JidnWub3P5eIV{ MUGyOFM2PzB{MB?=
HL-60 NFTLSVlHfW6ldHnvckBCe3OjeR?= MVeyJOK2VQ>? NWHEbHlxOTZiaB?= MnH4SG1UVw>? M3\rXIlvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| M4CySVI1OzNyME[4
HEK 293 M2XhZmZ2dmO2aX;uJGF{e2G7 M1XLN|ExKM7:TR?= M1HzPFUhcA>? NV\3bVB6TE2VTx?= MXTpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36= MXKyOFMzPDN4Nh?=
HEK 293 M2DqZ2Z2dmO2aX;uJGF{e2G7 NX[yZXk6OTBizszN NUnNeWhNPSCq M2X6PGROW09? M3XJO5N2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> M3f0TVI1OzJ2M{[2
SW480 NFHlUWhHfW6ldHnvckBCe3OjeR?= M2XJU|ExKM7:TR?= NISzVFYzOCCq M2HFXGROW09? M1PD[pN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> NVvrSnRrOjR|MkSzOlY>
HCSMCs MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW5NVAh|ryP MVKyOEBp MY\icI9kc3NiRlHCVFQucW6mdXPl[EBJS0GVTVOgdJJwdGmoZYLheIlwdg>? MkPqNlQ{OTJ|OEG=
PANC-1 MYLGeY5kfGmxbjDBd5NigQ>? NWLtUFdQOjBizszN MkjwOFghcA>? NH\PUZJqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kDPnD[GIHnuJJJme3CxboPlJJRwKHSqZTDQVGFT|rUEoHHnc45qe3UEoB?= NYCzXW41OjR{OUSxN|M>
A549 NUfDeYg6TnWwY4Tpc44hSXO|YYm= MV[zNEDPxE1? M4XRelAvPSCq MU\EUXNQ MkXsbY5pcWKrdIOgeIhmKHSqcn;tZolvNWmwZIXj[YQhUUxvOD;DXGNNQC2OdXOgZYN1cX[rdIm= M2\QNlI1Ojd5Nkm2
A549 Mlj1SpVv[3Srb36gRZN{[Xl? NGLrS40{OCEQvF2= Ml\kNE42KGh? NU\Ve454TE2VTx?= M{TP[YlvcGmkaYTzJJRpem:vYnnuMYlv\HWlZXSgR{9GSlEQsjDUbJIzOzYEoIDoc5NxcG:{eXzheIlwdg>? MmH6NlQzPzd4OU[=
MC-3 MULBdI9xfG:|aYOgRZN{[Xl? M4HSW|ExKM7:TR?= M3q4OFI1KGh? M1fTcpBwfGWwdHnheIVlKE2HU1OtbY5lfWOnZDDhdI9xfG:|aYOgbY4hKGOnbHzz MkDnNlQzPzB3MkO=
Raji  MoC0SpVv[3Srb36gRZN{[Xl? NH;pVZIyOCEQvF2= NIXBW4kyKGh? MmnjZoxw[2u|IHjzRmFHTiCrbnT1Z4VlKEW{a{GvNkBxcG:|cHjvdplt[XSrb36= M4fiZ|I1OjZ7NkOw
Raji  M3PQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TsN|ExKM7:TR?= NHzwVGQyKGh? NVrFTGVKcW6qaXLpeJMhfGinIHLhd4FtKG:{IHjzRmFHTi2|dHnteYxifGWmIHPlcIwheHKxbHnm[ZJifGmxbjDhcoQhfmmjYnnsbZR6 MXGyOFI3QTZ|MB?=
HT29 MlTxSpVv[3Srb36gRZN{[Xl? MVGxNEDPxE1? M3TXXFIhcA>? MWLpcohq[mm2czDv[kBLSUt{LDDFVmsyNzJiYX7kJHNVSVR|IIDoc5NxcG:{eXzheIlwdg>? NFPjc2MzPDJ4NUK5Ny=>
HepG2 NH\ZTW9CeG:ydH;zbZMhSXO|YYm= NYDmWGlmOjBizszN MoTJNlQhcA>? NIHHb4RqdmirYnn0d{BGWktzL{KgdIhwe3Cqb4L5cIF1cW:wIHHu[EBmdmijbnPld{BXSjFvaX7keYNm\CCjcH;weI9{cXN? NF;sdZkzPDJ2N{mwPS=>
HepG2 NHLn[mVHfW6ldHnvckBCe3OjeR?= NYrNN|RqOjBizszN MX6yJIg> M3zCb4VvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= M3jNZVI1OjR5OUC5
TE4 NIDTSoNHfW6ldHnvckBCe3OjeR?= NIW1bY8zOC93MD:xNFAh|ryP NYrTZ|ZJPDhiaB?= MnvySG1UVw>? NEfCfYZqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEXFc|UzPDJ2NECyNy=>
TE1 Mmf1SpVv[3Srb36gRZN{[Xl? NHLYb5MzOC93MD:xNFAh|ryP NI\KSmw1QCCq MYrEUXNQ Mn\FbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmPjNlQzPDRyMkO=
KYSE30 MlLrSpVv[3Srb36gRZN{[Xl? M4LJNFIxNzVyL{GwNEDPxE1? M1m1S|Q5KGh? NFnhc4tFVVOR NEe2VJlqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{PVelI1OjR2MEKz
TE1 M1\XOGZ2dmO2aX;uJGF{e2G7 NG\ZOlY2OCEQvF2= MXy0PEBp M3S2fmROW09? MmP3eZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MnrwNlQzPDRyMkO=
TE3 Mne5SpVv[3Srb36gRZN{[Xl? MkKwOVAh|ryP NU\QU2syPDhiaB?= M{fpemROW09? NXzyT25HfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= MVGyOFI1PDB{Mx?=
TE4 M4D1UmZ2dmO2aX;uJGF{e2G7 MlzBOVAh|ryP MYO0PEBp MVrEUXNQ M1OzO5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL MVOyOFI1PDB{Mx?=
TE5 NIn5b|FHfW6ldHnvckBCe3OjeR?= M1zEWFUxKM7:TR?= NHjKUGs1QCCq Ml;0SG1UVw>? M1y3d5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL M4nIXFI1OjR2MEKz
KYSE30 NHv0OG5HfW6ldHnvckBCe3OjeR?= MYO1NEDPxE1? MXW0PEBp Mlv5SG1UVw>? MVv1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? M37oOVI1OjR2MEKz
MKN7 MmG0SpVv[3Srb36gRZN{[Xl? NFfDdJc2OCEQvF2= M3LZT|Q5KGh? MlzaSG1UVw>? MVLpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| MViyOFI1PDB{Mx?=
OE19 NYf4RXNjTnWwY4Tpc44hSXO|YYm= NF\JfY42OCEQvF2= NEjkUlM1QCCq NXe0Z294TE2VTx?= MnvybY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= M4jTVFI1OjR2MEKz
KATOIII  M{DOWWZ2dmO2aX;uJGF{e2G7 MVK1NEDPxE1? NIfYc5k1QCCq MYnEUXNQ MlH3bY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MWKyOFI1PDB{Mx?=
NCI-N87  MYHGeY5kfGmxbjDBd5NigQ>? M1HZd|UxKM7:TR?= NHjYbZc1QCCq MXTEUXNQ NW\ERoRtcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MXmyOFI1PDB{Mx?=
NUGC3 M4LhOWZ2dmO2aX;uJGF{e2G7 M4Dub|UxKM7:TR?= MVu0PEBp MUPEUXNQ NYXiS2J4cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> Ml[1NlQzPDRyMkO=
NUGC2 M4PwSGZ2dmO2aX;uJGF{e2G7 NHX1clc2OCEQvF2= M3f4XFQ5KGh? M2PkT2ROW09? MWDpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| Ml[0NlQzPDRyMkO=
SGC-7901  MlT1RZBweHSxc3nzJGF{e2G7 M{\V[FIxKM7:TR?= NUjkcZVJOjRiaB?= Ml31bY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{ NFH4THQzPDJ2MUO1NS=>
MG-63 Mn[ySpVv[3Srb36gRZN{[Xl? MmD0NlAh|ryP MXGwMlUhcA>? NV3oSIJZ[myxY3vzJJRp\SCFSD3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKEWOS{GgdJJwfGWrbjDlfJBz\XO|aX;u NHLCc28zPDJ|OU[0NC=>
ARPE-19 M3;ofWZ2dmO2aX;uJGF{e2G7 NFPTelAzOCEQvF2= M2DhTVAvPSCq MVPpcohq[mm2czDBdIVtcW5vaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrJIFv\CCDa4S= M37FSFI1OjJ5OUG4
CRL-2302 NFOwN|lHfW6ldHnvckBCe3OjeR?= NVq0S2t6OjBizszN M2DKNFAvPSCq M4j0NolvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> MofZNlQzOjd7MUi=
MCF-7 MnHPSpVv[3Srb36gRZN{[Xl? MkjtNlAh|ryP NX7ycGg1OSCq NGD5XJVi[m:uaYPo[ZMh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUlugZ48ufHKnYYTt[Y51KHerdHigZ49vcnWpYYTl NV;LZoZYOjR{MU[yPFk>
MCF-7 MWDBdI9xfG:|aYOgRZN{[Xl? NELr[VIzOCEQvF2= NHn0RYgyKGh? MUjpcoNz\WG|ZYOgZ4F{eGG|ZT25JIVvgnmvZTDhZ5Rqfmm2eR?= MViyOFIyPjJ6OR?=
DLD-1  M1TMdGZ2dmO2aX;uJGF{e2G7 MojzNlDDqM7:TR?= NWTrclluPDhiaB?= MYjy[YR2[2W|IITo[UBDVkmSMzDlfJBz\XO|aX;uJJBz\S22cnXheIVlKHerdHigOU1igmFvZFO= Ml7oNlQzOTF3OEG=
HT-29 M1e1TGZ2dmO2aX;uJGF{e2G7 MVqyNOKh|ryP M{GwS|Q5KGh? NVrvPY9CemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE NVLpPWlPOjR{MUG1PFE>
7402 M2DJdWFxd3C2b4Ppd{BCe3OjeR?= MUSzNEDPxE1? NXHvXJZOPSCm NX\zeY8z\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? NWXuSXZmOjR{MUGyOVM>
7721 MmrzRZBweHSxc3nzJGF{e2G7 M{XlZlMxKM7:TR?= MYe1JIQ> NFnXZ3hl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v MoHiNlQzOTF{NUO=
SGC7901  MkTFRZBweHSxc3nzJGF{e2G7 M4XBSlUxyqEQvF2= NV6wfoMyOjRxNEivO|IhcA>? M4LKS2ROW09? NILreYhqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= MmjtNlQyPzh{NEC=
SMMC7721 MVPGeY5kfGmxbjDBd5NigQ>? NV7yRWN5OjVxNUCg{txO MX6yOEBp MWPzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA> NWXYT2l6OjRzNkiwOVY>
MCF-7 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25W2hsOTBizszN MWe0PIg> MV7EUXNQ NWjicoVNemW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R? MoniNlQyPjN2MES=
Caco-2 NFnScoZHfW6ldHnvckBCe3OjeR?= Mke1OVDDqM7:TR?= NIDhdVI1QGh? NHnCXHNFVVOR M3XlNoVvcGGwY3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhW0OQTkHBMGZZYUR|LNMgUGNVNMLiTF;YMOKhUEmIM1GsxsBbTzF4LNMgVGRGPkIEoHHu[OKhVEeDTGOxOuKh\2WwZYRCpINwNXS{ZXH0[YQhf2m2aDDE[Zg> NX\ucFI2OjRzNkG2PVU>
HAECs MYTGeY5kfGmxbjDBd5NigQ>? NXXEbVRHOTBizszN MlXtNUBp MofLxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25? NI\MfXIzPDF|NE[1Oy=>
Ca9-22 NFzrOopHfW6ldHnvckBCe3OjeR?= NGK1cVQ{KM7:TR?= Mk\CNUBp NWLF[Y1u[WKxbHnzbIV{KHSqZTDhZoltcXS7IH;mJGhjWiC2bzDpcoR2[2ViSVytPEBxem:mdXP0bY9v MmrWNlQyOjZ3M{K=
Ca9-22 NHvlUXZHfW6ldHnvckBCe3OjeR?= MWmzJO69VQ>? Mn;6NU8zKGh? NEnYfXVz\WS3Y3XzJGhjWi2rbnT1Z4VlKEGWRj2yJJBpd3OyaH;yfYxifGmxbh?= NXjoeJg4OjRzMk[1N|I>
AGS NWHucoRnTnWwY4Tpc44hSXO|YYm= NHHRe|MyOCEQvF5CpC=> M2\LZ|AvPSCq NUfRU|lscW6qaXLpeJMhfGinIIXwdoVofWyjdHnvckBw\iC2aHWgTWwuQCCpZX7l MonwNlQyODZzNk[=
Caco-2  M33kXWFxd3C2b4Ppd{BCe3OjeR?= NYL2c2ZmOTEEoN88US=> MX:yOOKhcA>? NXHSNmdl\GWlcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhPS2IVR?= NF:4SoQzPDB7NUi2Ny=>
HCT-8 MlnORZBweHSxc3nzJGF{e2G7 M1qyVVExyqEQvF2= NIDDTngzPMLiaB?= NInP[GFl\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[X M3TQS|I1ODl3OE[z
A549 NWP4UJc5TnWwY4Tpc44hSXO|YYm= MlqwOVDDqM7:TR?= NWXUeZR4OiCq M2nxWYJtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=> MYqyOFA3Pzd{Nx?=
HPMC MkXSSpVv[3Srb36gRZN{[Xl? MnL4NVDDqM7:TR?= MWq0PEBp M2PoT5JmfmW{c3XzJJRp\SClaHHu[4V{KGmwIHPlcIwhdW:{cHjvcI9ogSCrbnT1Z4VlKGK7IFjHVGRU MlLjNlQxPDJ6M{i=
HPMC NGfsSnhCeG:ydH;zbZMhSXO|YYm= MoPiNVDDqM7:TR?= M4nhUFI1yqCq Mne4doV3\XK|ZYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBJT1CGUx?= NG\vNlQzPDB2MkizPC=>
MGC803  MkGyRZBweHSxc3nzJGF{e2G7 NWPETpJ1OjEEoN88US=> NF;XN3oyKGh? MoC5bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU M2jpZ|I1ODJ5N{Ww
SGC7901 Ml3GRZBweHSxc3nzJGF{e2G7 M2Xa[lIxyqEQvF2= NUexN4tSOSCq M2XYcolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?= MljTNlQxOjd5NUC=
COLO205 M17mfGFxd3C2b4Ppd{BCe3OjeR?= NITlXZEyOC9{MD:0NEDPxE1? NEnDb4szPCCq MkfKbY5lfWOnczDEUmEhdGGmZHXyJIZwem2jdHnvci=> MWmyOFAyQTFyOB?=
G292  MXXBdI9xfG:|aYOgRZN{[Xl? MYSzNOKh|ryP MofBNkBp MXTy[ZN1d3KnczDjZZB{[WmlaX6tbY5lfWOnZDDj[YxtKGSnYYTo Mm\zNlQxOTJ7M{C=
BxPC-3 MlHvSpVv[3Srb36gRZN{[Xl? MmXnNVAh|ryPwrC= NGeydm43KGh? MmOybY5kemWjc3WgcYlTNTF2MzDlfJBz\XO|aX;u MlHONlM6PzN5MUC=
HPAF-II NFvufWRHfW6ldHnvckBCe3OjeR?= NXrRcYROOTBizszNxsA> M4rlNVYhcA>? NGHjbmNqdmO{ZXHz[UBucVJvMUSzJIV5eHKnc4Ppc44> M1f4W|I{QTd|N{Gw
HL-60 MWDBdI9xfG:|aYOgRZN{[Xl? MWq1NOKh|ryP NYPTNphVOSCq NVTRRWJsemW|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:|aYO= NEW0NFgzOzl2OEe1NS=>
HepG2 Mki4SpVv[3Srb36gRZN{[Xl? MXu0NEDPxE1? MVW2M|EzKGh? NHzKRW1qdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW|c3nvckBjgSCSTB?= NFuyWnAzOzl2Mki1NS=>
HUVECs NUHKZok{TnWwY4Tpc44hSXO|YYm= NV\rXYJrOjVizszN MoDjNUBp NV;QSXhkcW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36= M1zOZVI{QTBzMEC4
LNCaP  MmPoSpVv[3Srb36gRZN{[Xl? MorxNVAh|ryPwrC= MmnnNUBp NVf3Oo5E\GWlcnXhd4V{KHSqZTDFS2YhfXC{ZXf1cIF1\WRicD3ZRk0y MVqyN|g{QDNzOB?=
HL60  MVfGeY5kfGmxbjDBd5NigQ>? M{H5flIxyqEQvF2= M1:wfVczKGh? NY[0dpZbTE2VTx?= Ml\GbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= NVrROWFqOjN6MkW1PFU>
NB4  NVPzZXJbTnWwY4Tpc44hSXO|YYm= M1HBTFExKM7:TdMg M3vUflczKGh? NY[2NVM6TE2VTx?= MnHXbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= NVWyTWRuOjN6MkW1PFU>
EPOR/CR3 Mn7oSpVv[3Srb36gRZN{[Xl? M4\KOlUxyqEQvF2= M3vpfFMhcA>? NWTWNIptemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> Ml3JNlM5OjB5M{G=
HUASMCs MVzGeY5kfGmxbjDBd5NigQ>? MYOxNEDPxE4EoB?= MojKNlQhcA>? NYDMO5I5\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg Mki0NlM5OTZ2Nki=
HUASMCs M3XlUGZ2dmO2aX;uJGF{e2G7 M4Pze|ExKM7:TdMg NH[1THczPCCq NGi2bGVqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs NGnzc3QzOzhzNkS2PC=>
SGC7901 M2i3d2Z2dmO2aX;uJGF{e2G7 NUPyS4c1OTBizszNxsA> M17HdFI1KGh? NHPv[ZFqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? MlHGNlM4QTJ3OEi=
MKN45 M4P2UWZ2dmO2aX;uJGF{e2G7 NY\T[Y1xOTBizszNxsA> NHLN[3IzPCCq NVX6V4dycW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheGixc4Doc5J6dGG2ZXSgSXJMOS9{ NEHqdVczOzd7MkW4PC=>
SGC7901 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaNVAh|ryPwrC= NVf5SHJOOjRxNEivO|IhcA>? MnyybY5pcWKrdIOgZ4VtdCCpcn;3eIgh[29vdILlZZRm\CC5aYToJGRCWFR? MnS4NlM4QTJ3OEi=
MKN45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;IS|JsOTBizszNxsA> MX2yOE81QC95MjDo MUjpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? M33q[|I{Pzl{NUi4
SGC7901 NHjxNXVCeG:ydH;zbZMhSXO|YYm= NEXxRYMyOCEQvF5CpC=> NXTpd|dJOjRiaB?= MULpcoNz\WG|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? Moq4NlM4QTJ3OEi=
MKN45 NI[5UYtCeG:ydH;zbZMhSXO|YYm= NFe1[40yOCEQvF5CpC=> MXeyOEBp M2XsfYlv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NGT4XmwzOzd7MkW4PC=>
BxPC-3 cells MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLRenNROjEEoN88US=> Mn22NE42KGh? NF;4SY1qdmirYnn0d{BXTUeILVGtdoVofWyjdHXkJGhWXkWFIHfyc5d1cCCjbnSgeJVj\SCob4LtZZRqd25iaX7keYNm\CCkeTDQRXIuOiCDUB?= NELoT4UzOzd4NEC0Oi=>
NB4  M3XaemFxd3C2b4Ppd{BCe3OjeR?= M1zGOlExNzJyL{[wJO69VQ>? NIHXVVkyNjViaB?= NWDkSYs4TE2VTx?= NH;DSIdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTl[EB4cXSqIGDhZ4xqfGG6ZXy= NHvucVIzOzd|NUW0NS=>
HepG2  MV7GeY5kfGmxbjDBd5NigQ>? NInZe4QzOMLizszN NUDpT|I1OjRiaB?= MY\pcohq[mm2czD0bIUhUE9vMTDwdo91\WmwIHX4dJJme3Orb36gZ48ufHKnYYTl[EB4cXSqIH3leIZwem2rbh?= MmqwNlM4ODd4MEm=
HUVECs MoDvRZBweHSxc3nzJGF{e2G7 M3fMWVIwPCEQvF2= M4P0R|I1NzR6IHi= NXn0[YE4cW6mdXPld{Bk\WyuIHTlZZRp NYP2WXMyOjN5MEe1NlA>
KG-1  M4TyemFxd3C2b4Ppd{BCe3OjeR?= NIDqTJQzOMLizszN NIHTemgyOiCq NIfZTJpmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy MViyN|cxPjZ7MR?=
AML 1# NXHFcGpNSXCxcITvd4l{KEG|c3H5 MX[yNOKh|ryP M4mxVVEzKGh? MX7lcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx MWmyN|cxPjZ7MR?=
A2780  M3zkemZ2dmO2aX;uJGF{e2G7 NVni[2FZOjEEoN88US=> MlXGNUBp NGjUd45jdG:la4OgSHRETC2rbnT1Z4VlKESUNTDlfJBz\XO|aX;u NH\0N|QzOzZ7Nki2Ni=>

... Click to View More Cell Line Experimental Data

体内研究 在大脑缺血前30分钟用PD98059处理小鼠可以明显减轻伤害, 使脑梗塞的体积减小[4]。基于胰腺的湿重和组织学研究发现,提前30分钟用PD98059预处理 (10 mg/kg 静脉注射) 然后每小时注射一次蛙皮素连续三次的小鼠可以明显改善蛙皮素诱导的急性胰腺炎[7]。卡拉胶损伤一小时后用PD98059 (10 mg/kg) 对小鼠进行治疗可以发现与炎症相关的所有指标均有所下降[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外MEK激酶活性测定:

在含有44-kDa GST-MAPK 或者45-kDa GST-MEK1的体系中检测32P被掺入蛋白 MBP中的情况。 反应体系50 μL ,含有50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP, 加入10 μg GST-MEK1, 0.5 μg GST-MAPK和 40 μg MBP。30°C 孵育15 分钟, 加入Laemmli SDS 样品缓冲液终止反应。磷酸化的MBP 进行10% SDS-PAGE分析
细胞实验:[1]
+ 展开
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, 和K562
  • Concentrations: 溶于DMSO, 终浓度~100 μM
  • Incubation Time: 3 天, 或者7-10天
  • Method: 细胞按10,000-20,000个/mL的密度接种在多孔平板中进行单层生长。48小时后把不同浓度的PD98059 加到细胞培养基孵育3天。 然后通过胰酶将细胞从平板中消化下来并用Coulter 计数器计数。 将细胞按5,000-10,000每皿的浓度接种在35 mm的培养皿中,培养基中含有0.3% 的琼脂和期望浓度的PD98059,让细胞在软琼脂上生长.经过7-10天的生长, 可以借助解剖显微镜将可见的菌落数出来。
    (Only for Reference)
动物实验:[7]
+ 展开
  • Animal Models: 患有急性胰腺炎的雄性Sprague–Dawley 大鼠
  • Formulation: 溶于 DMSO, 用生理盐水稀释
  • Dosages: 10 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 267.28
化学式

C16H13NO3

CAS号 167869-21-8
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to formulate this inhibitor for i.p. injection?

  • 回答:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品

Tags: 购买PD98059 | PD98059供应商 | 采购PD98059 | PD98059价格 | PD98059生产 | 订购PD98059 | PD98059代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID